Stephen Liu, MD, provides an understanding of first-line treatment with chemotherapy for small cell lung cancer (SCLC), shares the emerging role of anti–PD-L1 inhibitors as combination therapy, and reviews options for relapsed/refractory SCLC.
SIGX1094 received fast track designation from the FDA for diffuse gastric cancer.
The Ministry of Health, Labour, and Welfare in Japan has approved epcoritamab for relapsed or refractory follicular lymphoma.
Tambiciclib plus zanubrutinib generated responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
The FDA granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive metastatic castration-resistant prostate cancer.
Petosemtamab/pembrolizumab received FDA breakthrough therapy designation for PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma.
The NCCN Guidelines for metastatic uveal melanoma now recommend HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant disease.
The FDA has granted priority review to zongertinib for unresectable or metastatic HER2-mutant advanced NSCLC.
R. Lor Randall, MD, FACS, discusses the enrollment criteria for a trial investigating surgical outcomes in patients with proximal femur metastases.
The FDA has accepted and granted priority review to an NDA for dordaviprone in recurrent H3K28M-mutant diffuse glioma.
Panelists discuss frontline maintenance therapies for advanced ovarian cancer, focusing on the impact of BRCA and HRD statuses on treatment selection and the choice between…
